Climb Bio, a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, has appointed two senior executives to strengthen its leadership team as the company advances its pipeline of B-cell targeted therapies. Edgar D. Charles, M.D., MSc joins as Chief Medical Officer, while Cindy J. Driscoll, MBA has been named Senior Vice President, Finance.
Experienced Immunology Leader Joins from Bristol Myers Squibb
Dr. Charles brings over 20 years of experience in immunology-focused pharmaceutical development, academic research, and clinical medicine to his new role. He joins Climb Bio from Bristol Myers Squibb (BMS), where he held clinical roles of increasing responsibility since 2015, leading the development of numerous therapeutic candidates through IND, Phase 1-4 clinical trials, and FDA product approval.
Most recently serving as Vice President and Senior Global Program Lead, Immunology at BMS, Dr. Charles led the immunology global program organization, overseeing strategy and execution across a diverse immune therapeutics pipeline spanning rheumatology, pulmonology, dermatology, and gastroenterology. Prior to BMS, he held roles at Merck & Co., leading global clinical development programs in infectious diseases and vaccines, and served as an Assistant Professor at Rockefeller University where his research focused on virus-induced autoimmunity and B cell biology.
"Dr. Charles is a highly respected physician-scientist with deep expertise in immunology and a proven track record translating scientific innovation into successful clinical development and product approvals," said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. "His R&D leadership experience, combined with two decades of development and operations expertise, will be invaluable as we execute our budoprutug and CLYM116 clinical studies and aim to maximize the expansive therapeutic potential of these promising programs."
Focus on B-Cell Targeted Therapeutics
Dr. Charles expressed enthusiasm about the company's pipeline, particularly the budoprutug program. "The encouraging budoprutug clinical data generated to date suggest that this program could have enormous therapeutic potential across various serious diseases where B cells play a central pathological role," he said. "I am thrilled to join Climb Bio as we embark on budoprutug clinical studies in our initial set of target indications and aim to move the subcutaneous formulation into clinical development."
Budoprutug is an anti-CD19 monoclonal antibody that has demonstrated B cell depletion and has potential to treat a broad range of B-cell mediated diseases. The company is also developing CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy, which Dr. Charles described as "a potentially best-in-class" therapeutic.
Financial Leadership Addition
Cindy Driscoll brings over 20 years of experience in the biotechnology industry, with deep expertise in building and scaling financial and administrative operations to support corporate growth. Prior to joining Climb Bio, she served as Senior Vice President of Finance at HC Bioscience, where she oversaw all financial reporting, budgeting, audit and tax functions, in addition to leading human resources, IT, and facilities.
Earlier in her career, Ms. Driscoll held senior finance roles at Magenta Therapeutics and Tokai Pharmaceuticals, where she managed the development of finance and G&A infrastructure to support IPOs and public financings totaling more than $450 million. She also led the implementation of Sarbanes-Oxley (SOX) compliance and drove operational efficiency across core administrative functions.
Equity Compensation Details
In connection with the appointments, Climb Bio granted inducement equity awards to both executives pursuant to the company's 2025 Inducement Plan. Dr. Charles received a non-statutory stock option to purchase up to 600,000 shares of common stock, while Ms. Driscoll was granted options for up to 200,000 shares. The awards were granted on June 17, 2025 with an exercise price of $1.20 per share, equal to the closing price on The Nasdaq Global Market that day.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary of each employee's start date and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service with the company.
